Portal Therapeutics, Inc.
Portal Therapeutics, Inc.
Explore linked clinical trials.2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, X-linked erythropoietic protoporphyria, erythropoietic protoporphyria, hepatic porphyria, hereditary disease, hereditary skin disorder, liver disorder, metabolic disease, porphyria, skin disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-15 | NCT07820085 | |
| Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, erythropoietic protoporphyria, hepatic porphyria, hereditary disease, hereditary skin disorder, liver disorder, metabolic disease, porphyria, skin disorder | Recruiting | Not stated | 2026-05-05 | NCT07567131 |